Evidence map›Paper›PMID 32991141›Full record

ArticleACS chemical neuroscience2020

Focus on Human Monoamine Transporter Selectivity. New Human DAT and NET Models, Experimental Validation, and SERT Affinity Exploration.

Gabriella Ortore, Elisabetta Orlandini, Laura Betti, Gino Giannaccini, Maria Rosa Mazzoni, Caterina Camodeca, Susanna Nencetti

Open access · hybridAbstract read
In one paragraph

Article in ACS chemical neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Gabriella OrtoreDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.ORCID 0000-0002-1541-6258
Elisabetta OrlandiniResearch Center "E. Piaggio", University of Pisa, Pisa 56122, Italy.
Laura BettiDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
Gino GiannacciniDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
Maria Rosa MazzoniDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
Caterina CamodecaDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.ORCID 0000-0002-8676-7311
Susanna NencettiDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.ORCID 0000-0002-3547-7277
University of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most commonly used antidepressant drugs are the serotonin transporter inhibitors. Their effects depend strongly on the selectivity for a single monoamine transporter compared to other amine transporters or receptors, and the selectivity is roughly influenced by the spatial protein structure. Here, we provide a computational study on three human monoamine transporters, i.e., DAT, NET, and SERT. Starting from the construction of hDAT and hNET models, whose three-dimensional structure is unknown, and the prediction of the binding pose for 19 known inhibitors, 3D-QSAR models of three human transporters were built. The training set variability, which was high in structure and activity profile, was validated using a set of in-house compounds. Results concern more than one aspect. First of all, hDAT and hNET three-dimensional structures were built, validated, and compared to the hSERT one; second, the computational study highlighted the differences in binding site arrangement statistically correlated to inhibitor selectivity; third, the profiling of new inhibitors pointed out a conservation of the inhibitory activity trend between rabbit and human SERT with a difference of about 1 order of magnitude; fourth, binding and functional studies confirmed 4-(benzyloxy)-4-phenylpiperidine

Indexed as

Norepinephrine Plasma Membrane Transport ProteinsSelective Serotonin Reuptake InhibitorsSerotonin Plasma Membrane Transport ProteinsAnimalsBinding SitesDopamine Plasma Membrane Transport ProteinsHumansModels, TheoreticalRabbitsDopamine Plasma Membrane Transport ProteinsNorepinephrine Plasma Membrane Transport ProteinsSelective Serotonin Reuptake InhibitorsSerotonin Plasma Membrane Transport Proteins3D-QSAR model4-phenylpiperidineDAThomology modelingNETSERT

Identifiers

PMID32991141
PMCPMC8015229
OpenAlexW3091367348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.